Mill Capital Management 13F: Cuts Zoetis (ZTS) Stake by $817K

Mill Capital Management trimmed its stake in Zoetis Inc. (ZTS) by 11,701 shares, reducing its total holdings to 162,288 shares. The information comes from the fund's latest Form 13F filing with the SEC on October 26, 2026.

ZTS Zoetis Inc.

$80.97 ▼ -34.69% year to date

1M 3M YTD

Daily close · Oct 26, 2026

Where Zoetis Inc. Fits in Mill Capital Management's Portfolio

Mill Capital's position in Zoetis represents 3.36% of its total reported 13F value. The reduction of 11,701 shares marks a 6.7% decrease in this position, which ranks 8th among the fund's 128 holdings.

Other Institutional Activity in Zoetis Inc.

Several other funds have also adjusted their positions in Zoetis. Fifth Third Wealth Advisors increased its stake by 12,137 shares, bringing its total to 49,817 shares valued at about $3.5 million. Meanwhile, Mondrian Investment Partners boosted its holdings by 434,964 shares, now holding 686,672 shares worth about $47.9 million. Conversely, Tokio Marine Asset Management cut its position by 33,723 shares, reducing its total to 23,209 shares valued at around $1.6 million.

Zoetis Inc. Stock Down 0.1%

As of October 27, 2026, Zoetis shares were recently trading around $80.95, which is about equal to the closing price of $80.97 on October 26, 2026. The stock is currently above its 50-day moving average by 8.3% but below its 200-day average by 14.3%. It remains significantly below its 52-week high of $147.93, down about 45.3% from that peak.

Recent Earnings

Zoetis reported trailing twelve-month revenue of approximately $9.53 billion, with a net margin of 27.7%. The next earnings report is scheduled for November 5, 2026.

Dividend

Zoetis pays an annual dividend rate of $2.12 per share, yielding about 2.62%. The dividend payout ratio stands at 33.9%.

Insider Buying and Selling at Zoetis Inc.

Recently, several insiders bought shares in Zoetis. Director Michael B. McCallister purchased 3,000 shares at an average price of $77.76 on May 11, 2026. Director Amelio Frank A. D. bought 6,650 shares at $75.39 on May 13, 2026, and Director Paul M. Bisaro acquired 2,000 shares at $75.88 on the same day.

Analysts Set New Price Targets

On August 11, 2026, Citigroup maintained a Buy rating with a target price of $96.00, while Stifel also maintained a Hold rating with a target of $80.00 on August 20, 2026. Analysts currently have a consensus recommendation of Buy with a mean price target of $93.00 based on 14 opinions.

About Zoetis Inc.

Zoetis Inc. develops and sells medicines, vaccines, and diagnostic products for the animal health industry. The company focuses on both companion animals and livestock, providing solutions that support animal health and welfare.

Bottom Line

Investors should keep an eye on Zoetis as it approaches its next earnings report on November 5, 2026. Mill Capital Management's recent trim in its position highlights the ongoing adjustments in the fund's strategy regarding this stock.